Table 3.
Clinical characteristics and treatment response in GRAALL and FRALLE treated patients according to fusion transcript status.
| Fusion groups | Negative n = 177 (75%) | ABL1 n = 15 (6%) | KMT2A/SET n = 19 (8%) | MLLT10 n = 20 (9%) | ETS n = 2 (1%) | other n = 2 (1%) | All n = 235 |
|---|---|---|---|---|---|---|---|
| Transcripts | NUP214-ABL1 (14) | SET-NUP214 (8) | PICALM-MLLT10 (16) | ETV6-NCOA2 (1) | NUP98-RAP1GDS1 (2) | ||
| BCR-ABL1 (1) | KMT2A-AFDN (5) | NAP1L1-MLLT10 (1) | TCF7-SPI1 (1) | ||||
| KMT2A-MLLT1 (4) | DDX3X-MLLT10 (2) | ||||||
| KMT2A-ELL (1) | XPO-MLLT10 (1) | ||||||
| KMT2A-? (1) | |||||||
| Clinical subsets | |||||||
| Age, median (range), y | 19.9 (1.1–59) | 15.9 (4.9–40.4) | 27.5 (8.5–44.6) | 29.8 (5.8–45.6) | 4.6–4.2 | 12–12.8 | 21 (1.1–58.9) |
| WBC, median (range) | 84.9 (2.8–788) | 98 (12–980) | 29.2 (2.8–195) | 28 (1.2–352) | 16–641 | 24.3–49 | 73.2 (1.2–980) |
| CNS involvement (%) | 20 (11) | 3 (20) | 1 (5.3) | 4 (20) | 0 | 0 | 28 (11.9) |
| Male, n (%) | 134 (76) | 12 (80) | 15 (79) | 12 (60) | 1 (50) | 2 (100) | 176 (74.9) |
| Treatment response, n (%) | |||||||
| Poor steroid response | 84 (47.4) | 11 (73.3) | 16 (84.2) | 14 (70.0) | 1 (50) | 0 | 126 (53.6) |
| CR | 161 (91) | 10 (66.7) | 19 (100) | 17 (85.0) | 2 (100) | 2 (100) | 211 (89.8) |
| MRD > 10–4 | 38 (29) | 5 (55.6) | 8 (53.3) | 7 (58.3) | 0 | 2 (100) | 59 (34.3) |
| Allo HSCT | 37 (22) | 2 (20) | 7 (36.8) | 6 (35.3) | 0 | 1 (50) | 59 (28) |
All subgroups characteristics are compared with the negative group. All results with p value ≤ 0.05 are displayed in bold.
allo HSCT allogeneic hematopoietic stem cell transplantation, CNS central nervous system, CR complete remission, MRD minimal residual disease, WBC white blood cell.